Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Monday
August 08, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
MONDAY, AUGUST 08, 2022
Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children

Coronavirus chronicle

22 October, 2021, 06:55 pm
Last modified: 22 October, 2021, 06:58 pm

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children aged 5-12 yrs to get Pfizer vaccine 
  • US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016

Pfizer/BioNTech Covid-19 vaccine shows 90.7% efficacy in trial in children

More than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy

22 October, 2021, 06:55 pm
Last modified: 22 October, 2021, 06:58 pm
A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters

The Pfizer /BioNTech Covid-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children 5 to 11 years old, the US drugmaker said on Friday.

Sixteen children in the trial who had received a placebo got Covid-19, compared with 3 who were vaccinated, Pfizer said in briefing documents submitted to the US Food and Drug Administration.

Because more than twice as many children in the 2,268-participant trial were given the vaccine than placebo, that equates to better than 90% efficacy.

Pfizer's clinical trial in those 5 to 11 years old was not primarily designed to measure efficacy against the virus. Instead, it compared the amount of neutralizing antibodies induced by the vaccine in the children to the response of older recipients in their adult trial.

Based on those results, Pfizer and BioNTech said last month that their Covid-19 vaccine induced a robust immune response in the children.

Outside advisors to the FDA are scheduled to meet on Tuesday to vote on whether to recommend that the agency authorize the vaccine for that age group.

The Pfizer/BioNTech vaccine already has US regulatory authorization for people who are at least 12 years old, including full FDA approval in August for those 16 and up.

Around 190 million people in the United States are fully vaccinated, including more than 11 million who are 12 to 17 years old that have received the Pfizer vaccine.

If the FDA authorizes the vaccine for children 5 to 11 years old, a group of advisors to the US Centers for Disease Control and Prevention will meet on Nov. 2 and 3 to make recommendations to the agency on how the shots should be administered. Most states wait for the CDC to sign off on recommendations for vaccines before they begin administering shots.

Top News / World+Biz

Pfizer / Pfizer vaccine / Pfizer Covid-19 Vaccine / BionTech Covid-19 Vaccine / Covid-19 vaccine on children

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • TBS file photo
    Now 99% Bangladesh products come under China’s duty-free offer
  • Photo: TBS
    Production loss feared as zone-wise industrial weekly closure mulled 
  • Representational image. File Photo: Minhaj Uddin/TBS
    LC settlement fell by $1.17b in July

MOST VIEWED

  • People line up for nucleic acid tests during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    China's Sanya holiday hotspot shuts duty-free malls, venues to curb Covid
  • FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea May 15, 2020, in this photo released by Kyodo. Mandatory credit Kyodo/via REUTERS
    North Korea marks end of first Covid wave, but risks persist
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    South Africa reports first death causally linked to Covid vaccine
  • 'Living with Covid': Where the pandemic could go next
    'Living with Covid': Where the pandemic could go next
  • A worker, wearing a protective suit following the coronavirus disease (COVID-19) outbreak, transports luggage on the tarmac of Wuhan Tianhe International Airport, on a hot summer day in Wuhan, Hubei province, China July 14, 2022. cnsphoto via REUTERS
    China's Wuhan locks down 1m residents amid new Covid cases
  • Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel
    Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children aged 5-12 yrs to get Pfizer vaccine 
  • US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016

Features

Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

17h | Mode
Infograph: TBS

Why a drastic fuel price hike is dangerous

1d | Panorama
A fuel price hike to fuel agony

A fuel price hike to fuel agony

1d | Panorama
Kamal Uddin Mazumder. Sketch: TBS

Rising foreign debt and balance of payments deficit: Does Bangladesh need to worry?

1d | Thoughts

More Videos from TBS

How Google Maps operates in Bangladesh

How Google Maps operates in Bangladesh

7h | Videos
Is BPC really in loss?

Is BPC really in loss?

8h | Videos
Reasons behind Putin-Erdogan's meeting in Sochi

Reasons behind Putin-Erdogan's meeting in Sochi

12h | Videos
Dr Jamaluddin Ahmed talks about recent fuel price hike

Dr Jamaluddin Ahmed talks about recent fuel price hike

12h | Videos

Most Read

1
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

2
Housing projects sprouting up by Dhaka-Mawa expressway
Real Estate

Housing projects sprouting up by Dhaka-Mawa expressway

3
July remittance hits two-year high
Economy

July remittance hits two-year high

4
Infographic: TBS
Banking

Dollar rate will be left to market after two months: Governor

5
Bangladesh to resume talks for Ukrainian wheat import
Economy

Bangladesh to resume talks for Ukrainian wheat import

6
A liquefied natural gas (LNG) tanker is tugged towards a thermal power station in Futtsu, east of Tokyo, Japan November 13, 2017. REUTERS/Issei Kato/File Photo
Energy

Summit proposes long-term LNG supply to Petrobangla

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net